Abstract
We describe a patient with chronic myelogenous leukemia (CML) who developed drug-induced agranulocytosis. A 75-year-old female was diagnosed with CML in December 2001. She had been receiving imatinib therapy for more than five years. In August 2007, she was hospitalized due to a severe neutropenia 10 days after colonoscopy. She was diagnosed as having agranulocytosis induced by colonoscopy premedication including scopolamine butylbromide and flumazenil. Severe neutropenia was resolved by G-CSF treatment without CML progression. Agranulocytosis in patients with CML is rare, but potentially lethal. Here, we report the clinical course in this patient.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Agranulocytosis / chemically induced*
-
Agranulocytosis / etiology
-
Benzamides
-
Butylscopolammonium Bromide / adverse effects*
-
Colonoscopy
-
Female
-
Flumazenil / adverse effects*
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Neutropenia / drug therapy
-
Neutropenia / etiology
-
Piperazines / therapeutic use
-
Premedication / adverse effects*
-
Pyrimidines / therapeutic use
-
Treatment Outcome
Substances
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Granulocyte Colony-Stimulating Factor
-
Butylscopolammonium Bromide
-
Flumazenil
-
Imatinib Mesylate